comparemela.com

Latest Breaking News On - Asco 2021 - Page 1 : comparemela.com

ASCO 2021 Podium Presentation on Agendia FLEX Study Shows Clinical & Molecular Differences in Tumors of African American and Caucasian Patients with HR+ Breast Cancer, Underscores Importance of Genomic Insights to Understand Disparities in Outcomes

Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting revealed new data from the national FLEX registry that identify differences in tumor biology between ethnic groups that can lead to meaningful treatment decisions, reinforcing the need for appropriate representation of diverse patient populations in breast cancer studies.

California
United-states
Irvine
Amsterdam
Noord-holland
Netherlands
American
Patricia-robinson
Kent-hoskins
Terri-clevenger
American-society-of-clinical-oncology
University-of-illinois-cancer-center

ASCO: J&J's subcutaneous bispecifics tackle multiple myeloma in phase 1

May 24, 2021 8:00am The phase 1 trials focused on gauging the safety and tolerability of the bispecifics, but the efficacy results look “extremely promising” to a very sick patient group, the majority of whom had no luck with their last line of therapy, Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit. (Hailshadow/GettyImages) Johnson & Johnson finished the FDA filing for its anti-BCMA CAR-T in multiple myeloma last month, but that doesn’t mean it’s letting off the gas. The drugmaker revealed phase 1 data for two bispecific antibodies showing they shrank the tumors of about 70% of patients whose cancer got worse despite trying several other treatments, including the three main types of myeloma-fighting drugs.

United-states
American
Craig-tendler
Amgen-kyprolis
Amgen
Pfizer
Glaxosmithkline
American-society-for-clinical-oncology
Bristol-myers-squibb
Johnson
American-society
Clinical-oncology

ASCO: Roche's Tecentriq grabs I-O's first win in post-surgery lung cancer, but it's limited—and an FDA approval could be, too

May 19, 2021 5:00pm Roche s Tecentriq cut the risk of post-surgery cancer recurrence or death by 34% against best supportive care in patients with PD-L1-postivie stage II to IIIA non-small cell lung cancer. (Roche) In early cancer that’s amenable to surgery, a field viewed as the next battleground for PD-1/L1 immunotherapies, Roche’s Tecentriq has claimed the first win in non-small cell lung cancer. But the drug’s role, at least in some patients, remains unclear. Tecentriq slashed the risk of cancer recurrence or death after surgery by 34% in a study slated for the virtual American Society of Clinical Oncology meeting next month but only in patients with stage II to IIIA disease whose tumors bore the PD-L1 biomarker.

United-states
American
Bill-anderson
Roche-genentech
Peter-welford
Charles-fuchs
Roche-tecentriq
Astrazeneca
American-society-of-clinical-oncology
European-medicines-agency
American-society
Clinical-oncology

Don't Shed Your Sweats Yet! The Year's 8 Hottest Living Room Design Trends Bring the Cozy, Comfy Vibes

Skip to main content Currently Reading Don t Shed Your Sweats Yet! The Year s 8 Hottest Living Room Design Trends Bring the Cozy, Comfy Vibes Don t Shed Your Sweats Yet! The Year s 8 Hottest Living Room Design Trends Bring the Cozy, Comfy Vibes This year is all about relaxed environments that prioritize comfort. Here s exactly what you can expect to see in living room design trends in 2021. Margaret Heidenry, provided by FacebookTwitterEmail Much as we might hate to admit it, the living room of 2020 was good to us. It was a space that became our office, our classroom, and comforted us during all the stay-at-home orders of the past months (and months).

New-york
United-states
Katie-burnet
Shane-pliska
Emilie-navarro
Susann-goerg
Shelby-greene
New-york-city
Living-spaces
Rumor-designs
Steamboat-springs

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.